The Trademark Trial and Appeal Board (TTAB) ruled in favor of Finnegan client Combe Inc. in another case involving the company’s VAGISIL trademark. The panel held that Marke Enterprises cannot register “VAGISERT” for its feminine care products, as they are “legally identical” to Combe’s VAGISIL line of feminine care products and therefore would cause confusion in the marketplace. Marke Enterprises argued that “vagi-“ is a generic prefix referring to an anatomic structure, but Combe argued the prefix is not typically used to identify any particular type of product or body part. The TTAB agreed with Combe, citing Combe’s reputation in the market and stating that consumers aren’t conditioned to distinguish between VAGISIL, VAGISTAT, and VAGISERT based on "minute differences."
Read “Vagisil Maker Gets Rival's 'Vagisert' TM Blocked at TTAB”
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Commentary
New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret
September 21, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.